Xhale Awarded NIH/NIMH SBIR Grant for Monitoring Microbicide Gel Use

GAINESVILLE, FL April 16, 2014 – Xhale SMART, Inc.

Xhale, Inc. has been awarded a 2-year Complex Technologies Phase 1 National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grant in the amount of $622,000 by the National Institute of Mental Health (NIMH). This is the seventh SBIR grant awarded to Xhale.

The grant, entitled “SMART: A Breath-based Adherence Technology to Monitor HIV Microbicide Gel Use,” will be used to apply Xhale’s breath-based SMART® (Self Monitoring and Reporting Therapeutics) technology to seek to develop an alternative, breath-based, adherence monitoring tool for investigators studying microbicide administration. The SBIR program is a highly competitive program that encourages domestic small businesses to engage in Federal Research/Research and Development (R/R&D) that has the potential for commercialization. Through a competitive awards-based program, SBIR enables small businesses to explore their technological potential and move innovative products towards commercialization.

This grant will bring together researchers from Xhale, Inc., RTI International, and the University of California – San Francisco, and will be led by Donn Dennis, M.D., F.A.H.A., the Chief Scientific Officer of Xhale, Inc. In addition to his work with Xhale, Dr. Dennis is a professor in the Departments of Anesthesiology, Psychiatry and Pharmacology & Experimental Therapeutics in the College of Medicine at the University of Florida.

About Xhale, Inc., Xhale SMART, Inc. and Xhale Assurance, Inc.

Xhale, Inc. is a medical technology company developing and commercializing patient-centric monitoring solutions for the healthcare industry. Xhale, Inc. is focused on developing two broad technology platforms. Through its Xhale SMART, Inc. subsidiary, Xhale, Inc. is developing a medication adherence monitoring technology which focuses on monitoring patient adherence to medication regimens established in protocols for investigation drugs in clinical trials. Through its Xhale Assurance, Inc. subsidiary, Xhale, Inc. is developing a patient monitoring technology designed to improve and expand the use of conventional pulse oximetry used in hospitals and other clinical settings to monitor critical patient parameters, as well as to increase the number of parameters which can be measured. Xhale, Inc.’s first product based on this technology, the Assurance® Alar One-Sense™ pulse oximetry sensor, received marketing clearance in the United States in April 2013. The Assurance® Alar One-Sense™ pulse oximetry sensor is a disposable sensor placed on a patient’s nasal ala which transmits heart rate and blood oxygenation information to an oximetry monitor.


Download PDF: Xhale Awarded SBIR Grant for Monitoring Microbicide Gel Use